hero-bg

Impact of COVID-19 pandemic on EQA timetables

We are aware that the coronavirus (COVID-19) outbreak is putting sustained pressure on genomic testing services globally. EMQN has issued a statement on its impact on EQA timetables for 2020.

The EQA distributions planned for May and June 2020 have been postponed - please click the button below to see which schemes have been affected.

EMQN and GenQA collaborate to launch pilot EQA for advanced (metastatic) Prostate Cancer

Manchester, UK, 6th March 2020: EMQN CIC today announced it is collaborating with GenQA to launch a pilot EQA scheme for HRR gene testing in patients with advanced Prostate Cancer.

EMQN and GenQA collaborate to launch an EQA Scheme for cfDNA testing for EGFR mutations in lung cancer

Manchester, UK, 26th February 2020: EMQN CIC today announced it is collaborating with GenQA to launch an EQA Scheme for cfDNA testing for EGFR mutations in lung cancer.

EMQN launches pilot External Quality Assessment (EQA) scheme for PIK3CA testing in advanced (metastatic) Breast Cancer

Manchester, UK, 4th February 2020: EMQN CIC (“EMQN” or “the Company”), a global leader in external quality assessment (EQA) / proficiency testing (PT) for genomics, today announced it is launching a pilot EQA scheme for PIK3CA testing in patients with advanced or metastatic breast cancer.

We are a not-for-profit organisation promoting quality in genetic testing by establishing, harmonising and disseminating best practice.

We provide ISO 17043 accredited External Quality Assessment (EQA) or Proficiency Testing (PT) schemes which are designed to test the whole analytical process of a molecular diagnostics laboratory including the ability to interpret data in the light of clinical information supplied with a referral, and to produce a clear and accurate report.

    Membership

    Membership of EMQN gives your laboratory access to world class resources in genomics to help improve your performance.

    EMQN Membership

    Best Practice

    We facilitate the development and publication of best practice guidelines. To participate in a best practice meeting you must be a registered member of the network.

    Best Practice with EMQN

    The latest news and press releases

    Posted 7 days ago

    AZ sponsor cfDNA testing EQA scheme

    Astrazeneca sponsor EQA scheme for cfDNA testing for EGFR mutations in Lung cancer On the 26th February 2020 EMQN CIC and GenQA…
    Posted 2 weeks ago

    EMQN statement: impact of COVID-19 pandemic on EQA timetables

    We are aware that the coronavirus (COVID-19) outbreak is putting sustained pressure on genomic testing services globally. Therefore, EMQN has…
    Translate »